# US 2019/0315883 A1 · Novel immunoconjugates

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0315883 A1
- Document ID: US20190315883A1
- Status: Published application
- Kind: A1
- Application number: 16/430,301
- Filed: 2019-06-03
- Published: 2019-10-17
- Earliest claimed: 2011-04-29
- Assignees: Roche Glycart AG
- Applicants: Roche Glycart AG
- Inventors: Oliver AST; Peter BRUENKER; Thomas U. HOFER; Ralf HOSSE; Christian Klein; Ekkehard MOESSNER; Pablo UMANA
- Web page: https://patentgrep.com/patent/US20190315883A1

## CPC

- C07K 16/40: against enzymes
- A61K 38/2013: {IL-2}
- A61K 47/6813: {the drug being a peptidic cytokine, e.g. an interleukin or interferon}
- A61K 47/6843: {the antibody targeting a material from animals or humans}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61K 47/6853: {Carcino-embryonic antigens}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- C07K 14/5434: {IL-12}
- C07K 14/55: IL-2
- C07K 16/18: against material from animals or humans
- C07K 16/283: {against Fc-receptors, e.g. CD16, CD32, CD64 (CD23 C07K16/2851)}
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- C07K 16/30: from tumour cells
- C07K 16/3007: {Carcino-embryonic Antigens}
- C07K 16/46: Hybrid immunoglobulins (hybrids of an immunoglobulin with a peptide not being an immunoglobulin C07K19/00)
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 2039/505: {comprising antibodies}
- C07K 14/52: Cytokines; Lymphokines; Interferons
- C07K 2317/21: from primates, e.g. man
- C07K 2317/41: Glycosylation, sialylation, or fucosylation
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/524: CH2 domain
- C07K 2317/55: Fab or Fab'
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/71: Decreased effector function due to an Fc-modification
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2319/00: Fusion polypeptide
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C07K 2319/74: containing a fusion for binding to a cell surface receptor
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention generally relates to antigen-specific immunoconjugates for selectively delivering effector moieties that influence cellular activity. More specifically, the invention provides novel immunoconjugates comprising a first antigen binding moiety, an Fc domain and a single effector moiety. In addition, the present invention relates to polynucleotides encoding such immunoconjugates, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the immunoconjugates of the invention, and to methods of using these immunoconjugates in the treatment of disease.

## Claims

### Claim 1

An immunoconjugate comprising a first antigen binding moiety, an Fc domain consisting of two subunits, and an effector moiety, wherein not more than one effector moiety is present.

### Claim 2 (depends on 1)

The immunoconjugate of claim 1, wherein said Fc domain comprises a modification promoting heterodimerization of two non-identical polypeptide chains.

### Claim 3 (depends on 2)

The immunoconjugate of claim 2, wherein said modification is a knob-into-hole modification, comprising a knob modification in one of the subunits of the Fc domain and a hole modification in the other one of the two subunits of the Fc domain.

### Claim 4 (depends on 1)

The immunoconjugate of claim 1, wherein said Fc domain is engineered to have altered binding to an Fc receptor and/or altered effector function.

### Claim 5 (depends on 1)

The immunoconjugate of claim 1, wherein the effector moiety is a cytokine.

### Claim 6 (depends on 5)

The immunoconjugate of claim 5, wherein said cytokine is IL-2.

### Claim 7 (depends on 1)

An isolated polynucleotide encoding the immunoconjugate of claim 1 or a fragment thereof.

### Claim 8 (depends on 7)

An expression vector comprising the isolated polynucleotide of claim 7.

### Claim 9 (depends on 8)

A host cell comprising the expression vector of claim 8.

### Claim 10 (depends on 9)

A method of producing the immunoconjugate comprising a first antigen binding moiety, an Fc domain consisting of two subunits, and an effector moiety, wherein not more than one effector moiety is present, comprising culturing the host cell of claim 9 under conditions suitable for the expression of the immunoconjugate and optionally recovering the immunoconjugate.

### Claim 11 (depends on 1)

A pharmaceutical composition comprising the immunoconjugate of claim 1 and a pharmaceutically acceptable carrier.

### Claim 12 (depends on 1)

A method of treating a disease in an individual, comprising administering to said individual a therapeutically effective amount of a composition comprising the immunoconjugate of claim 1 in a pharmaceutically acceptable form.

### Claim 13

A conjugate comprising a first Fab molecule which does not specifically bind to any antigen, an Fc domain consisting of two subunits, and an effector moiety, wherein not more than one effector moiety is present.

### Claim 14 (depends on 13)

The conjugate of claim 13, wherein said effector moiety is fused to the amino- or carboxy-terminal amino acid of one of said two subunits of the Fc domain, optionally through a linker peptide.

### Claim 15 (depends on 13)

The conjugate of claim 13, wherein said first Fab molecule is fused to the amino-terminal amino acid of one of said two subunits of the Fc domain, optionally through a linker peptide or an immunoglobulin hinge region.

### Claim 16 (depends on 13)

The conjugate of claim 13, wherein said Fc domain is engineered to have altered binding to an Fc receptor and/or altered effector function.

### Claim 17 (depends on 13)

The conjugate of claim 13, wherein the conjugate comprises a first and a second Fab molecule.

### Claim 18 (depends on 17)

The conjugate of claim 17, wherein said first and said second Fab molecule and said Fc domain are part of an immunoglobulin molecule.

### Claim 19 (depends on 18)

The conjugate of claim 18, wherein said effector moiety is fused to the carboxy-terminal amino acid of one of the immunoglobulin heavy chains, optionally through a linker peptide.

### Claim 20 (depends on 13)

The conjugate of claim 13, wherein the effector moiety is a cytokine.

### Claim 21 (depends on 13)

An isolated polynucleotide encoding the conjugate of claim 13 or a fragment thereof.

### Claim 22 (depends on 21)

An expression vector comprising the isolated polynucleotide of claim 21.

### Claim 23 (depends on 21)

A host cell comprising the expression vector of claim 21.

### Claim 24 (depends on 23)

A method of producing the conjugate comprising a first Fab molecule which does not specifically bind to any antigen, an Fc domain consisting of two subunits, and an effector moiety, wherein not more than one effector moiety is present, comprising culturing the host cell of claim 23 under conditions suitable for the expression of the conjugate and optionally recovering the conjugate.

### Claim 25 (depends on 13)

A pharmaceutical composition comprising the conjugate of claim 13 and a pharmaceutically acceptable carrier.

### Claim 26 (depends on 13)

A method of treating a disease in an individual, comprising administering to said individual a therapeutically effective amount of a composition comprising the conjugate of claim 13 in a pharmaceutically acceptable form.
